Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Kim, Jun Gyu ^a   Kang, Min Jueng ^a   Yoon, Young Kwang ^a   Kim, Hwang Phill ^a   Park, Jinah ^a   Song, Sang Hyun ^a   Han, Sae Won ^a   Park, Jong Wan ^a   Kang, Gyeong Hoon ^a   Kang, Keon Wook ^a   Oh, Do Youn ^a   Im, Seock Ah ^a   Bang, Yung Jue ^a   Yi, Eugene C ^a   Kim, Tae You ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIGITUMUMAB; GLYCAN; HETERODIMER; INSULIN RECEPTOR; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DIMERIZATION; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; GROWTH INHIBITION; HETERODIMERIZATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; SENSITIVITY ANALYSIS; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; CELL STRAIN HEPG2; CHEMISTRY; DRUG ANTAGONISM; DRUG SCREENING; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTEIN QUATERNARY STRUCTURE; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; DIMERIZATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; GLYCOSYLATION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; PROTEIN STRUCTURE, QUATERNARY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863378814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033322     Document Type: Article

References (45)

1. Ouban A, Muraca P, Yeatman T, Coppola D, (2003) Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 34: 803-808.
2. Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, et al. (1999) Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 5: 1935-1944.
3. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, et al. (1993) Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53: 3736-3740.
4. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, et al. (2001) The IGF system in thyroid cancer: new concepts. Mol Pathol 54: 121-124.
5. Yu H, Rohan T, (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92: 1472-1489.
6. Baserga R, (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9: 753-768.
7. Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R, (2008) Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 7: 2575-2588.
8. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, et al. (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63: 8912-8921.
9. Nahta R, Hortobagyi GN, Esteva FJ, (2003) Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8: 5-17.
10. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, et al. (2010) Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65: 765-773.
11. Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, et al. (2009) Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. J Thorac Oncol 4: 1397-1403.
12. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, et al. (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063-2073.
13. Heller G, Zochbauer-Muller S, (2010) Insulin-like growth factor type I receptor: a new target in the treatment of non-small cell lung cancer patients. memo-Magazine of European Medical Oncology 3: 81-84.
14. Olmos D, Postel-Vinay S, Molife L, Okuno SH, Schuetze SM, et al. (2010) Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. The lancet oncology 11: 129-135.
15. Jassem J, Langer C, Karp D, Mok T, Benner R, et al. (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28: 539a.
16. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, et al. (1999) Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19: 3278-3288.
17. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, et al. (2002) Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143: 3259-3267.
18. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, et al. (1999) Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 18: 2471-2479.
19. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, et al. (2002) A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87: 245-254.
20. De Meyts P, Whittaker J, (2002) Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1: 769-783.
21. Olson TS, Bamberger MJ, Lane MD, (1988) Post-translational changes in tertiary and quaternary structure of the insulin proreceptor. Correlation with acquisition of function. J Biol Chem 263: 7342-7351.
22. Moxham CP, Duronio V, Jacobs S, (1989) Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264: 13238-13244.
23. Soos MA, Siddle K, (1989) Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. Biochem J 263: 553-563.
24. Soos MA, Whittaker J, Lammers R, Ullrich A, Siddle K, (1990) Receptors for insulin and insulin-like growth factor-I can form hybrid dimers. Characterisation of hybrid receptors in transfected cells. Biochem J 270: 383-390.
25. Vella V, Sciacca L, Pandini G, Mineo R, Squatrito S, et al. (2001) The IGF system in thyroid cancer: new concepts. Molecular Pathology 54: 121-124.
26. Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R, (1999) Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie 81: 403-407.
27. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R, (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30: 586-623.
28. Frattali AL, Pessin JE, (1993) Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. J Biol Chem 268: 7393-7400.
29. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, et al. (2002) Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277: 39684-39695.
30. Pandini G, Wurch T, Akla B, Corvaia N, Belfiore A, et al. (2007) Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 43: 1318-1327.
31. Zha J, O'Brien C, Savage H, Huw LY, Zhong F, et al. (2009) Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther 8: 2110-2121.
32. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, et al. (2008) Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68: 8039-8048.
33. Frasca F, Pandini G, Vigneri R, Goldfine ID, (2003) Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis 17: 73-89.
34. Gong Y, Yao E, Shen R, Goel A, Arcila M, et al. (2009) High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PloS one 4: e7273.
35. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, et al. (1990) Elevated insulin receptor content in human breast cancer. J Clin Invest 86: 1503-1510.
36. Belfiore A, (2007) The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 13: 671-686.
37. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, et al. (1986) Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503-2512.
38. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, et al. (2009) Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-2452.
39. Gualberto A, Hixon M, Karp D, Li D, Green S, et al. (2010) Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. British journal of cancer 104: 68-74.
40. Ku JL, Park JG, (2005) Biology of SNU Cell Lines. Cancer Res Treat 37: 1-19.
41. Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P, (1992) In-gel digestion of proteins for internal sequence analysis after one-or two-dimensional gel electrophoresis. Analytical biochemistry 203: 173-179.
42. Yi EC, Lee H, Aebersold R, Goodlett DR, (2003) A microcapillary trap cartridge microcapillary high performance liquid chromatography electrospray ionization emitter device capable of peptide tandem mass spectrometry at the attomole level on an ion trap mass spectrometer with automated routine operation. Rapid communications in mass spectrometry 17: 2093-2098.
43. Eng JK, McCormack AL, Yates III, Jr, (1994) An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. Journal of the American Society for Mass Spectrometry 5: 976-989.
44. Keller A, Nesvizhskii AI, Kolker E, Aebersold R, (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Analytical chemistry 74: 5383-5392.
45. Nesvizhskii AI, Keller A, Kolker E, Aebersold R, (2003) A statistical model for identifying proteins by tandem mass spectrometry. Analytical chemistry 75: 4646-4658.